Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Estrella Immunopharma, Inc. Director's Dealing 2025

Oct 1, 2025

34647_dirs_2025-10-01_98623c91-f8d4-4a09-8edc-793badaea08a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Estrella Immunopharma, Inc. (ESLA)
CIK: 0001844417
Period of Report: 2025-09-22

Reporting Person: Jia Dengyao (Director)

More from Estrella Immunopharma, Inc.

Proxy Solicitation & Information Statement 2026
May 27
Interim / Quarterly Report 2026
May 15
Annual Report 2026
Apr 30
Regulatory Filings 2026
Feb 13
Regulatory Filings 2026
Jan 26
Regulatory Filings 2026
Jan 22
Regulatory Filings 2026
Jan 16
Regulatory Filings 2026
Jan 13
Regulatory Filings 2026
Jan 6
Regulatory Filings 2026
Jan 6
View all filings →